PRESS RELEASE
Accera, Inc. to Present at Rodman & Renshaw 9th Annual Healthcare Conference
Broomfield, CO, October 30, 2007 - Accera Inc. announced today that the company will be participating in the Rodman & Renshaw 9th Annual Healthcare Conference November 5-7 at the Palace Hotel in New York City. President and CEO Dr. Steve Orndorff will present the company November 7 at 12:40 p.m. in the Hubbard Room.
Dr. Orndorff will provide an overview of Accera and its technology platform as well as a summary of the positive data from the company’s Phase IIb studies of its lead drug candidate, Ketasyn™ (AC-1202) in Alzheimer’s disease (AD) and age-associated memory impairment (AAMI). He will also discuss Accera’s plans to commercialize Ketasyn as a medical food for the treatment of AD in 2008.
About Accera, Inc.
Based in Broomfield, CO, Accera, Inc. is a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases. The company’s lead candidate, Ketasyn™ (AC-1202), is a first-in-class molecule that earlier this year completed successful Phase II clinical trials for Alzheimer’s disease (AD) and age-associated memory impairment (AAMI). Accera plans to self-commercialize Ketasyn as a medical food for the treatment of AD in the US in 2008. A key element of Accera’s strategy is to work with corporate partners to commercialize Ketasyn in non-U.S. markets, and to develop other proprietary small molecule compounds in its pipeline as ethical drugs for a range of memory and cognition disorders associated with neurological conditions and aging. www.accerapharma.com
About Ketasyn™
Brain imaging techniques performed on Alzheimer’s patients reveal a dramatically decreased uptake of glucose, the brain’s preferred source of energy. Known as neuronal hypometabolism, this condition resembles diabetes in the brain, or Type III diabetes. Ketasyn™ (AC-1202) is an orally available, liquid compound that is efficiently converted into ketone bodies, an alternative energy source that the brain can use even when glucose metabolism is impaired. By preserving glucose-deprived neurons, Ketasyn™ demonstrates neuroprotective and disease modifying potential in a number other neurodegenerative diseases characterized by neuronal hypometabolism.
Earlier this year, Accera completed two separate Phase IIb studies of Ketasyn™ in AD and Age-Associated Memory Impairment (AAMI). Ketasyn was shown to significantly improve memory and cognition using a battery of neuropsychometric tests, including ADAS-Cog, the FDA’s gold-standard efficacy measure for AD drugs. Ketasyn™ was also well tolerated in both indications, even when taken in addition to existing AD drugs, making it a promising candidate for a polypharmacy approach to treating AD. This first-in-class compound is also being evaluated in age-associated memory impairment, Parkinson’s disease, and selected orphan drug indications. Accera plans to commercialize Ketasyn as a medical food for the treatment of AD in 2008.
About Medical Foods
The Food and Drug Administration defines a medical food as a food to be consumed or administered orally under medical supervision for the dietary management of a disease or condition for which specific nutritional requirements have been scientifically proven. Medical foods are specially formulated and processed to meet these nutritional requirements, which modification of the diet alone cannot satisfy. Medical foods may be prescribed by a physician for a patient actively receiving medical attention for a specific disease or condition, and are subject to the general food and safety labeling requirements of the Federal Food Drug and Cosmetic Act.
###